A dual folic acid (FA) and matrix metalloproteinase (MMP) proximity-activated targeting (PAT) smart polymeric nanoparticle (SPN) has been developed for tumor-specific siRNA delivery. The nanocarrier was designed to be activated only in regions of elevated MMP activity, which triggers exposure of concealed FA ligands and targeted uptake by cells expressing folate receptors. Efficient dual targeting (nanocarrier cell uptake and siRNA knockdown dependent on both pre-activation with MMP-7 and folate receptor mediated endocytosis) was achieved with optimally-formulated mixed micelle nanoparticles with 25-50 mol% FA-SPN titrated with the PAT-SPN. PAT/FA-SPN demonstrated improved delivery and gene silencing relative to our recentlypublished PAT-only micelles (MMP-activated micelles lacking FA). This PAT/FA-SPN design showcases a successful platform for improved specificity and efficacy for targeted siRNA delivery to cancer metastases.
INTRODUCTION
To increase the tumor specificity of therapeutic siRNA delivery, we designed a multifunctional nanocarrier that targets tissues where there is a colocalization of cell-surface FA receptors and elevated MMP-7 activity, which are both hallmarks of the breast cancer microenvironment. 1 The PAT/FA-SPN design masks the FA ligand under a PEG "cloak" that is removed by MMP-7 proteolysis, which reveals the FA and triggers uptake by folate receptor-expressing cells ( 
EXPERIMENTAL METHODS
PAT-SPN polymer synthesis was carried out as previously described 2 with substitution of a 20 kDa Yshaped PEG to improve shielding of the interior cationic charge and FA ligands. Briefly, site-selective chemistry was used to attach the PEG and a reversible additionfragmentation chain transfer (RAFT) polymerization chain transfer agent (CTA) to the opposite ends of the peptide to form PEG-peptide-macroCTA. FA-macroCTA was made by conjugation of an FA and a CTA to the opposite ends of a 2 kDa PEG linker. Two sequential RAFT polymerizations were carried out with each of these macro-CTAs to grow a diblock copolymer
(SPN), resulting in PAT-SPN and FA-SPN, respectively. The polymers were characterized by NMR and size exclusion chromatography (SEC). Mixed micelle nanoparticles (PAT/FA-SPN) were assembled from various ratios of the FA-SPN and PAT-SPN polymers. Particle diameters were measured by dynamic light scattering (DLS) and transmission electron microscopy (TEM). The MMP-7-dependent proximity activation was confirmed by SEC, DLS, and zeta potential. Enhanced intracellular uptake of PAT/FA-SPNs pretreated with MMP-7 was investigated in FA receptor expressing MDA-MB-231 and MCF-7 breast cancer cells by confocal microscopy and flow cytometry. PAT/FA-SPN knockdown of the model protein luciferase was used to validate the dual targeting mechanism in luciferase-expressing MDA-MB-231 cancer cells (MDA-231-Luc).
RESULTS AND DISCUSSION
PEG-peptide-p(DMAEMA)-b-p(DMAEMA-BMA-PAA) (PAT-SPN) was found to have M n =43.6 kDa and a polydispersity (PDI) =1.28, and FA-PEG-p(DMAEMA)-b-p(DMAEMA-BMA-PAA) (FA-SPN) had M n =46 kDa and PDI=1.27. These amphiphilic polymers were coassembled in aqueous media into 50 nm micelles, presenting zeta potentials of -0.21, -0.20, +1.75, +6.71, and +12.2 mV for mixed micelles consisting 0, 25, 50, 75, 100 mol% FA, respectively. MMP-7 responsiveness was confirmed by DLS, which showed decreased particle diameter (e.g., 25% FA micelle diameter decreased from 54 to 48 nm), and simultaneous increase in zeta potential (-0.20 to +8.11 mV). These data suggest that MMP-7 removal of the PEG corona from the nanocarriers revealed the underlying polycationic charge from the pDMAEMA block. Cytocompatibility was confirmed in MDA-231-Luc cells treated with nanocarriers loaded with nonspecific siRNA. Following pre-treatment with exogenous MMP-7 to mimic the proteolytically active environment of MMP-7-rich human breast cancers, cellular uptake was elevated 2.3-fold for single targeting PAT-SPN and 4.6-fold for dual targeting PAT/FA-SPN, as compared to intact PAT-SPN, (Fig. 2) . Cell uptake of intact PAT/FA-SPN (0 and 25% FA) not exposed to MMP was statistically equivalent to untreated cells (NT) (Fig. 2A) . This result suggests that the 20 kDa Y-shaped PEG effectively shields underlying cationic charge and FA and also blocks nonspecific interaction of the nanocarriers with cells. The observed lack of nonspecific cellular binding is significantly improved relative to our previously reported PAT-SPN which possessed a shorter, 5 kDa linear PEG. 2 As anticipated, increasing the proportion of FA-SPN polymer (75-100%) reduced the dependency of cellular uptake on MMP-7 activity. Addition of excess FA in the media to competitively bind to FA receptors reduced the uptake of the FA-SPNcontaining micelles, consistent with FA receptordependent uptake following MMP activation. Both nanocarriers (with 5 kDa linear or 20 kDa Y-shaped PEG) exhibited significantly greater hemocompatibility as compared to Lipofectamine®, displaying nearly undetectable interaction with blood cells and serum proteins after 1h incubation at 37 o C under conditions in which 60-70% of the Lipofectamine® complex was lost due to cellular and protein interactions (data not shown). The PAT/FA-SPNs pre-activated with MMP-7 also mediated significantly greater siRNA gene suppression relative to controls (no MMP activation / free FA addition to block FA receptors), confirming the efficient dual FA-PAT targeting and endosomal escape (Fig. 3) . 
CONCLUSION
Dual MMP-and FA-targeted siRNA carriers (PAT/FA-SPNs) to treat breast cancer metastases were successfully designed, constructed, and assessed in in vitro model systems. Two endosomolytic, amphiphilic polymers were co-assembled to form micelles that display FA only in response to MMP-7 proteolysis. Cellular uptake experiments confirmed increased delivery of nucleic acids in cancer cells with elevated FA receptor expression following the treatment of nanocarriers with MMP-7, mimicking the proteolytically active environment of human breast cancers. In addition, gene knockdown studies showed significant suppression of target protein levels only in microenvironments that provide both pathologically elevated MMP-7 concentration and cells expressing the FA receptor. These data indicate that this novel nanoscale vehicle has important advantages in tissue targeting and effective therapeutic delivery to breast cancer cells for gene knockdown.
